Analysts Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Target Price at $28.50

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have been given an average recommendation of “Moderate Buy” by the nine analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $28.50.

Several analysts have commented on GLUE shares. Guggenheim reaffirmed a “buy” rating and set a $28.00 price objective on shares of Monte Rosa Therapeutics in a research note on Tuesday. JPMorgan Chase & Co. dropped their target price on Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Wells Fargo & Company decreased their price target on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Weiss Ratings lowered shares of Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Finally, Zacks Research raised shares of Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, Director Anthony M. Manning sold 10,000 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director owned 10,000 shares of the company’s stock, valued at approximately $231,100. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sharon Townson sold 6,000 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the completion of the sale, the insider directly owned 67,845 shares in the company, valued at approximately $1,581,466.95. The trade was a 8.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 79,603 shares of company stock valued at $1,725,081 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Monte Rosa Therapeutics during the second quarter worth about $165,603,000. Price T Rowe Associates Inc. MD grew its holdings in Monte Rosa Therapeutics by 10.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after buying an additional 481,844 shares during the period. Vanguard Group Inc. increased its stake in shares of Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after acquiring an additional 257,547 shares during the last quarter. State Street Corp lifted its holdings in shares of Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after acquiring an additional 1,260,707 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Monte Rosa Therapeutics by 39,776.6% in the second quarter. California State Teachers Retirement System now owns 1,311,543 shares of the company’s stock worth $31,739,000 after acquiring an additional 1,308,254 shares during the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Price Performance

Monte Rosa Therapeutics stock opened at $13.38 on Monday. The stock has a market cap of $1.14 billion, a PE ratio of -7.60 and a beta of 1.59. The stock’s fifty day moving average is $19.72 and its two-hundred day moving average is $18.63. Monte Rosa Therapeutics has a 1-year low of $4.60 and a 1-year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $8.97 million during the quarter, compared to analysts’ expectations of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. On average, research analysts expect that Monte Rosa Therapeutics will post -1.32 earnings per share for the current fiscal year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.